GT Biopharma (NASDAQ:GTBP) Announces Quarterly Earnings Results, Misses Expectations By $0.03 EPS

GT Biopharma (NASDAQ:GTBP) released its quarterly earnings results on Friday. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03), FiscalAI reports.

GT Biopharma Stock Performance

Shares of GTBP opened at $0.39 on Friday. The stock has a market capitalization of $14.03 million, a P/E ratio of -0.06 and a beta of 0.64. The company’s fifty day moving average is $0.40 and its two-hundred day moving average is $0.57. GT Biopharma has a 1 year low of $0.26 and a 1 year high of $3.85.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GT Biopharma in a research report on Friday, April 10th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, GT Biopharma has a consensus rating of “Sell”.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).